A recent review highlighted the emerging role of pharmacogenetic screening for the prevention of severe cutaneous adverse drug reactions (ADRs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and hypersensitivity syndrome reaction (HSR).
Actemra: first IL-6 receptor inhibitor for RA; BuTrans: first once-weekly transdermal opioid; Onsolis: opioid buccal film for breakthrough cancer pain; Victoza: first GLP-1 analogue for type 2 diabetes